Compared to gefitinib treatment, BEZ235 or PD0332991 could inhibit tumor growth, and the combination of gefitinib, BEZ235 and PD0332991 even dramatically suppressed tumor growth in the EGFR-TKI resistant xenografts of PC9/ER (Fig. 6d-f). This evidence concerns the gene EGFR and neoplasm.